FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387598082> ?p ?o ?g. }

• W4387598082 abstract "To describe the pattern of anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) utilization in the Tuscany region, Italy, and the variation of triptan consumption after treatment initiation.Given the recent commercialization of anti-CGRP mAbs as migraine preventive medications, real-world evidence on their patterns of utilization and their impact on migraine abortive medication use is still limited.A retrospective, descriptive, cohort study on the real-world utilization of anti-CGRP mAbs was performed using the population-based regional administrative database of Tuscany. Patients with ≥1 anti-CGRP mAb dispensing (namely erenumab, galcanezumab, fremanezumab) between April 1, 2019, and September 30, 2021, were identified. The first dispensing was the cohort entry (CE). New users (NUs) were patients with no anti-CGRP mAb dispensing before CE. Kaplan-Meier (KM) curves were plotted to describe the cumulative probability of remaining with the initial anti-CGRP mAb during a 15-month follow-up period as a measure of treatment persistence. Among NUs with ≥2 triptan dispensings during the 6 months before CE (i.e., baseline), the mean monthly number of triptan dosage units dispensed was measured in five consecutive follow-up time windows (months 1-3, 4-6, 7-9, 10-12, 13-15) and the difference from the baseline was calculated.A total of 624 NUs (erenumab = 295, galcanezumab = 223, fremanezumab = 106) were identified, of whom 188 (78%) were women. Mean age was 49.2 years (standard deviation [SD] = 12.6). The survival to discontinuation at 6, 12, and 15 months was about 69%, 48%, and 6%, respectively. The survival to switch was about 6% at 15 months. The observed variation of triptan consumption at 3/6/9/12/15 months and the corresponding SD was -4.4 [8.2]/-5.2 [9.0]/-5.5 [9.2]/-5.4 [9.2]/-4.5 [10.0], respectively.Patient demographics reflect the place of these medications in therapy. Overall, findings seem to indicate a favorable tolerability and effectiveness profile. Further studies are warranted to better establish the long-term comparative effectiveness, safety, and cost effectiveness of anti-CGRP mAbs compared to other preventive medications." @default.
• W4387598082 created "2023-10-14" @default.
• W4387598082 creator A5000033590 @default.
• W4387598082 creator A5015926077 @default.
• W4387598082 creator A5065242873 @default.
• W4387598082 creator A5072103443 @default.
• W4387598082 creator A5076732352 @default.
• W4387598082 creator A5084301044 @default.
• W4387598082 creator A5085817840 @default.
• W4387598082 date "2023-10-13" @default.
• W4387598082 modified "2023-10-14" @default.
• W4387598082 title "Patterns of anti‐CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy" @default.
• W4387598082 cites W1802284765 @default.
• W4387598082 cites W1966819377 @default.
• W4387598082 cites W2001650386 @default.
• W4387598082 cites W2079170220 @default.
• W4387598082 cites W2346275821 @default.
• W4387598082 cites W2768357559 @default.
• W4387598082 cites W2770965214 @default.
• W4387598082 cites W2885920730 @default.
• W4387598082 cites W2893311239 @default.
• W4387598082 cites W2895868360 @default.
• W4387598082 cites W2921922848 @default.
• W4387598082 cites W2922174162 @default.
• W4387598082 cites W2939159833 @default.
• W4387598082 cites W3010985439 @default.
• W4387598082 cites W3015052705 @default.
• W4387598082 cites W3094653551 @default.
• W4387598082 cites W3115361485 @default.
• W4387598082 cites W3157009111 @default.
• W4387598082 cites W3162538154 @default.
• W4387598082 cites W3168130561 @default.
• W4387598082 cites W3181707881 @default.
• W4387598082 cites W3185049798 @default.
• W4387598082 cites W3198032575 @default.
• W4387598082 cites W3199105267 @default.
• W4387598082 cites W3201983205 @default.
• W4387598082 cites W3215142683 @default.
• W4387598082 cites W3215819634 @default.
• W4387598082 cites W4210569896 @default.
• W4387598082 cites W4210809802 @default.
• W4387598082 cites W4211212370 @default.
• W4387598082 cites W4225370603 @default.
• W4387598082 cites W4226126197 @default.
• W4387598082 cites W4226295842 @default.
• W4387598082 cites W4239989451 @default.
• W4387598082 cites W4282934967 @default.
• W4387598082 cites W4283161974 @default.
• W4387598082 cites W4295517433 @default.
• W4387598082 cites W4309655248 @default.
• W4387598082 cites W4318263236 @default.
• W4387598082 cites W4324309808 @default.
• W4387598082 cites W4353045942 @default.
• W4387598082 cites W4385498082 @default.
• W4387598082 doi "https://doi.org/10.1111/head.14639" @default.
• W4387598082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37830925" @default.
• W4387598082 hasPublicationYear "2023" @default.
• W4387598082 type Work @default.
• W4387598082 citedByCount "0" @default.
• W4387598082 crossrefType "journal-article" @default.
• W4387598082 hasAuthorship W4387598082A5000033590 @default.
• W4387598082 hasAuthorship W4387598082A5015926077 @default.
• W4387598082 hasAuthorship W4387598082A5065242873 @default.
• W4387598082 hasAuthorship W4387598082A5072103443 @default.
• W4387598082 hasAuthorship W4387598082A5076732352 @default.
• W4387598082 hasAuthorship W4387598082A5084301044 @default.
• W4387598082 hasAuthorship W4387598082A5085817840 @default.
• W4387598082 hasBestOaLocation W43875980821 @default.
• W4387598082 hasConcept C118303440 @default.
• W4387598082 hasConcept C126322002 @default.
• W4387598082 hasConcept C163170386 @default.
• W4387598082 hasConcept C167135981 @default.
• W4387598082 hasConcept C170493617 @default.
• W4387598082 hasConcept C187212893 @default.
• W4387598082 hasConcept C2778541695 @default.
• W4387598082 hasConcept C2778715236 @default.
• W4387598082 hasConcept C2908647359 @default.
• W4387598082 hasConcept C71924100 @default.
• W4387598082 hasConcept C72563966 @default.
• W4387598082 hasConcept C99454951 @default.
• W4387598082 hasConceptScore W4387598082C118303440 @default.
• W4387598082 hasConceptScore W4387598082C126322002 @default.
• W4387598082 hasConceptScore W4387598082C163170386 @default.
• W4387598082 hasConceptScore W4387598082C167135981 @default.
• W4387598082 hasConceptScore W4387598082C170493617 @default.
• W4387598082 hasConceptScore W4387598082C187212893 @default.
• W4387598082 hasConceptScore W4387598082C2778541695 @default.
• W4387598082 hasConceptScore W4387598082C2778715236 @default.
• W4387598082 hasConceptScore W4387598082C2908647359 @default.
• W4387598082 hasConceptScore W4387598082C71924100 @default.
• W4387598082 hasConceptScore W4387598082C72563966 @default.
• W4387598082 hasConceptScore W4387598082C99454951 @default.
• W4387598082 hasLocation W43875980821 @default.
• W4387598082 hasLocation W43875980822 @default.
• W4387598082 hasOpenAccess W4387598082 @default.
• W4387598082 hasPrimaryLocation W43875980821 @default.
• W4387598082 hasRelatedWork W1987721600 @default.
• W4387598082 hasRelatedWork W2031603956 @default.
• W4387598082 hasRelatedWork W2064438027 @default.
• W4387598082 hasRelatedWork W2360693916 @default.

• next